RPG Life Sciences Limited (RPGLIFE) - Total Assets

Latest as of March 2026: Rs7.93 Billion INR ≈ $85.78 Million USD

Based on the latest financial reports, RPG Life Sciences Limited (RPGLIFE) holds total assets worth Rs7.93 Billion INR (≈ $85.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check RPGLIFE cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

RPG Life Sciences Limited - Total Assets Trend (2005–2026)

This chart illustrates how RPG Life Sciences Limited's total assets have evolved over time, based on quarterly financial data. Explore RPG Life Sciences Limited long-term investment allocation to see how much of total assets are deployed in long-term investments.

RPG Life Sciences Limited - Asset Composition Analysis

Current Asset Composition (March 2026)

RPG Life Sciences Limited's total assets of Rs7.93 Billion consist of 70.5% current assets and 29.5% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 24.2%
Accounts Receivable Rs1.17 Billion 14.7%
Inventory Rs1.24 Billion 15.6%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs81.10 Million 1.0%
Goodwill Rs0.00 0.0%

Asset Composition Trend (2005–2026)

This chart illustrates how RPG Life Sciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of RPG Life Sciences Limited.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: RPG Life Sciences Limited's current assets represent 70.5% of total assets in 2026, an increase from 29.2% in 2005.
  • Cash Position: Cash and equivalents constituted 24.2% of total assets in 2026, up from 0.3% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2005.
  • Asset Diversification: The largest asset category is inventory at 15.6% of total assets.

RPG Life Sciences Limited Competitors by Total Assets

Key competitors of RPG Life Sciences Limited based on total assets are shown below.

Company Country Total Assets
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥14.18 Billion
SIMCERE PHARMAC. GRP LTD
F:S2P
Germany €14.73 Billion
Curaleaf Holdings Inc.
TO:CURA
Canada CA$2.88 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Walvax BioTech
SHE:300142
China CN¥11.13 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion

RPG Life Sciences Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.48 3.88 2.21
Quick Ratio 2.71 3.11 1.47
Cash Ratio 0.00 1.17 0.00
Working Capital Rs3.99 Billion Rs3.45 Billion Rs961.60 Million

RPG Life Sciences Limited - Advanced Valuation Insights

This section examines the relationship between RPG Life Sciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 5.71
Latest Market Cap to Assets Ratio 0.05
Asset Growth Rate (YoY) 20.6%
Total Assets Rs7.93 Billion
Market Capitalization $407.47 Million USD

Valuation Analysis

Below Book Valuation: The market values RPG Life Sciences Limited's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: RPG Life Sciences Limited's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for RPG Life Sciences Limited (2005–2026)

The table below shows the annual total assets of RPG Life Sciences Limited from 2005 to 2026.

Year Total Assets Change
2026-03-31 Rs7.93 Billion
≈ $85.78 Million
+20.58%
2025-03-31 Rs6.58 Billion
≈ $71.14 Million
+28.26%
2024-03-31 Rs5.13 Billion
≈ $55.46 Million
+22.30%
2023-03-31 Rs4.19 Billion
≈ $45.35 Million
+21.69%
2022-03-31 Rs3.45 Billion
≈ $37.27 Million
+13.59%
2021-03-31 Rs3.03 Billion
≈ $32.81 Million
+13.74%
2020-03-31 Rs2.67 Billion
≈ $28.85 Million
+6.17%
2019-03-31 Rs2.51 Billion
≈ $27.17 Million
-13.74%
2018-03-31 Rs2.91 Billion
≈ $31.50 Million
+18.27%
2017-03-31 Rs2.46 Billion
≈ $26.63 Million
+20.00%
2016-03-31 Rs2.05 Billion
≈ $22.19 Million
+4.23%
2015-03-31 Rs1.97 Billion
≈ $21.30 Million
+0.43%
2014-03-31 Rs1.96 Billion
≈ $21.20 Million
-4.71%
2013-03-31 Rs2.06 Billion
≈ $22.25 Million
+12.50%
2012-03-31 Rs1.83 Billion
≈ $19.78 Million
-4.19%
2011-03-31 Rs1.91 Billion
≈ $20.64 Million
+14.06%
2010-03-31 Rs1.67 Billion
≈ $18.10 Million
-0.33%
2009-03-31 Rs1.68 Billion
≈ $18.16 Million
-4.27%
2008-03-31 Rs1.75 Billion
≈ $18.97 Million
-14.63%
2007-03-31 Rs2.05 Billion
≈ $22.22 Million
-6.36%
2006-03-31 Rs2.19 Billion
≈ $23.73 Million
-6.71%
2005-03-31 Rs2.35 Billion
≈ $25.44 Million
--

About RPG Life Sciences Limited

NSE:RPGLIFE India Drug Manufacturers - Specialty & Generic
Market Cap
$407.47 Million
Rs37.68 Billion INR
Market Cap Rank
#13445 Global
#666 in India
Share Price
Rs2278.10
Change (1 day)
-1.04%
52-Week Range
Rs1744.00 - Rs2657.80
All Time High
Rs2828.55
About

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. … Read more